



台灣外科醫學會 TSA 2024



113年度外科聯合學術研討會

2024 Annual Meeting of Taiwan Surgical Association

KAOHSIUNG,
TAIWAN



地點 | 高雄醫學大學暨附設中和紀念醫院

日期 | 2024年3月16-17日

台灣腹膜惡性腫瘤醫學會

Taiwan Peritoneal Oncological Association (TWPOA)

Taiwan Peritoneal Oncological Association (TWPOA) was established in May 2019. TWPOA aims to promote the research of peritoneal malignancy (peritoneal metastasis from intraperitoneal cancers), educational training and academic conferences on the prevention and diagnosis and treatment of peritoneal malignancy, so as to allow surgeons/physicians to have an opportunity to exchange experience and technical learning, and at the same time, it is hoped that through the promotion of TWPOA, more surgeons/physicians can understand cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), and also educate the public to have correct concepts.

Taiwan started late in this field, and it was not until 1994 that surgeons to perform the first case of CRS/HIPEC in Taiwan. However, the majority of surgeons/physicians still do not clearly know such a treatment method. Over the years, more patients have been treated, accumulating results are better than in

the past. In medical field, more papers have also been published. Therefore, more and more surgeons/physicians gradually recognize this treatment method and accept CRS/HIPEC. In recent years, due to the introduction of HIPEC equipment into Taiwan, more surgeons have devoted themselves to perform HIPEC. All intraperitoneal malignant tumors, such as gastric cancer, colorectal cancer, appendix cancer, ovarian cancer, pseudomyxoma peritonei, mesothelioma, hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, etc., once intra-peritoneal metastasis occurs, are suitable for CRS/HIPEC.

President: Jin-Tung Liang, M.D., Ph.D.

Secretary General: Yu-Tso Liao M.D

Website: *www.twpoa.org.tw*